NCT00784875
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
See it on ClinicalTrials.gov ↗407 people
59%
41%
240 womenmiddle line = equal numbers167 men
- Phase
- PHASE2
- Paid for by
- Eli Lilly and Company
- Finished
- 2010-02
- Health conditions
- Primary Insomnia, Secondary Insomnia
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 52.27 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 75.2% · Black / African American 17.7% · Hispanic / Latina 5.7% · Asian 1.2% · Not reported 0.2%
Women left out
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“Body Mass Index \> 33”
- No seizures
Women with epilepsy or past seizures were turned away.
“History of seizures”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Severe or unstable psychiatric or medical illness”
- No cancer
Women with current or past cancer were turned away.
“History of breast cancer”
Study titles and rules are shown in their original English.